Previous Close | 0.9200 |
Open | 0.9204 |
Bid | 0.8900 x 800 |
Ask | 1.0300 x 800 |
Day's Range | 0.9100 - 0.9720 |
52 Week Range | 0.7400 - 9.1600 |
Volume | |
Avg. Volume | 507,972 |
Market Cap | 40.205M |
Beta (5Y Monthly) | 1.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.8140 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.57 |
Subscribe to Yahoo Finance Plus to view Fair Value for AVRO
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
Avrobio Inc (NASDAQ: AVRO) announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in infantile-onset Pompe disease. Pompe disease is a lysosomal disorder caused by a mutation in the GAA gene. The lack of the enzyme encoded by GAA results in a toxic buildup of glycogen throughout the body and central nervous system. The results demonstrate that gene therapy using hematopoietic stem cells (HSC) significantly reduced the toxic accumulation of glycogen in a mouse
CAMBRIDGE, Mass., May 18, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the "Disease models and Clinical Applications: Musculo-skeletal Diseases" poster session at the American Society of Gene